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A Randomised Controlled Trial of Prostar PlusTM for Haemostasis in
Patients After Coronary Angioplasty
T. Noguchi, S. Miyazaki*, S. Yasuda, T. Baba, H. Sumida, I. Morii, S. Daikoku, Y. Goto and H. Nonogi
Division of Cardiology, National Cardiovascular Center, Osaka, Japan
Objectives: to clarify the efficacy and safety of Prostar PlusTM, a new percutaneous vascular surgical device (PVS) for
vascular haemostasis.
Design: prospective randomised controlled trial.
Methods: a consecutive series of 60 patients were randomised to either PVS (n=30) or conventional manual compression
(n=30) following coronary angioplasty or stenting with femoral access using an 8-F sheath.
Results: PVS significantly shortened the time to haemostasis (10 s.d. 3 vs. 27 s.d. 9 min, p<0.001), ambulation (2.2 s.d. 0.9
vs. 11.0 s.d. 1.4 h, p<0.001), and discharge (2.2 s.d. 0.4 vs. 3.1 s.d. 0.7 days, p<0.01), compared with the manual
compression group with no major complications. PVS also increased patient comfort assessed by using a visual-analogue
scale method. Although these clinical benefits reduced the hospital cost ($1301 s.d. 248 vs. 1613 s.d. 460, p<0.05), the
cost of the PVS device (>$350) cancelled the cost-saving benefit.
Conclusions: this randomised study indicates that Prostar PlusTM is safe, more effective and comfortable than conventional
manual compression.
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Introduction experience with this device.4,10,11 We therefore under-
took a prospective randomised controlled trial in
The risk for arterial access-site complications become patients who underwent coronary angioplasty, to as-
sess not only the efficacy and safety of the device,more frequent with the use of larger devices or ag-
gressive anticoagulation in the recent interventional but also its effects on length of hospital stay, patient
comfort, and hospital cost.era.1,2 Because of these complications, patients may
require blood transfusion, surgical repair, and ex-
tended hospital stays.3 In order to improve haemostasis
and to avoid re-bleeding, patients are often required
Methodsto rest for an extended period of time (approximately
12 h in case of coronary angioplasty or stenting using Between July 1997 and January 1998, 341 patients who8-F catheter). Vascular haemostasis devices, deployable underwent angioplasty or stenting in our hospital werewithout compression and anticoagulation reversal, considered for inclusion in this study. The followingmay obviate some of these problems. One haemostasis exclusion criteria were applied:device recently developed is the collagen plug
(VasoSealÔ). However, its application has not sig- (1) arterial access at a site other than the right or left
femoral artery;nificantly decreased vascular complications, par-
ticularly if anticoagulation is used.5–8,13 (2) emergency procedure;
(3) continued use of warfarin prior to the procedure;The Prostar PlusÔ (Perclose Inc., Menlo Park, CA,
U.S.A.; see Figs 1 and 2) is a new device for vascular (4) haematoma formation occurring during the pro-
cedure;haemostasis. Arterial puncture sites are closed per-
cutaneously with two non-absorbable 4.0-gauge su- (5) history of claudication due to arteriosclerosis ob-
literans or vascular surgery which involved grointures.9 There have been several small reports of clinical
area such as aortofemoral bypass surgery;
* Please address all correspondence to: S. Miyazaki, Division of (6) unwillingness or inability to provide written, in-Cardiology, Department of Medicine, National Cardiovascular Cen-
ter, 5-7-1 Fujishiro-dai, Suita, Osaka, 565-8565, Japan. formed consent.
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Randomization was carried out in the cardiac cath- between sheath removal and the first observed hae-
mostasis. If bleeding occurred later, this was noted,eterisation laboratory, using consecutive sealed en-
velopes. This study protocol was approved by the and any additional haemostasis time was added to
the original time.Human Ethics Committee of the hospital. Written and
witnessed informed consent was obtained from all Safety endpoints included vascular injury (need for
vascular repair, pseudoaneurysm) and bleeding com-patients prior to their inclusion in the trial.
All procedures were performed by the femoral ap- plications (bleeding requiring transfusion, haematoma
<5 or[5 cm). When there was suspicion of a vascularproach using an 8-F sheath and catheter. Following
angioplasty or stenting, patients randomised to the complication, ultrasound investigation of the femoral
artery was performed. Approximately 24 h after sheathPVS group remained in the laboratory on the cath-
eterisation table, where the sheath was removed and removal, all patients were interviewed and examined
by a single observer. Patient comfort was assessedProstar PlusÔ deployed immediately after an-
gioplasty, using the manufacturer’s recommended during and after the haemostasis procedure (=before
ambulation) in both groups, using two 10-point stand-technique, which has been described in detail pre-
viously.4 The patients randomised to conventional ard visual analogue scales (VAS).14 Patient discomfort
was rated on a 0-to-10 scale, in which rate 0 is “no pain”manual compression were managed in a standard
fashion on the cardiology ward, where all arterial and rate 10 is “maximal degree of pain” experienced by
the patient, respectively. All patients in the PVS groupsheaths were removed.
All patients received oral aspirin (162 mg/day) be- were additionally asked, “which would you prefer if
an intervention is repeated?”.fore coronary angioplasty or stenting. After sheath
insertion, a bolus of 5000 IU of heparin was ad- Hospital costs and charges were calculated at the
National Cardiovascular Centre (Osaka, Japan), andministered intravenously. Doses of 2000 IU of heparin
were given every hour during the angioplasty. In then expressed in 1998 U.S. dollars (1 U.S. dollar=145
Japanese yen). Treatment costs include costs of therapystent cases, a bolus of 5000 IU of heparin was added
immediately before stent implantation. Following stent (including drugs and testing during follow-up after
angioplasty or monitoring and surveillance of patients)implantation, ticlopidine was started in addition to
oral antiplatelet and heparin infusion was continued and costs of treating complications or side-effects.
Neither the actual expense for angioplasty nor indirectovernight at a rate of 400–800 IU/h, to maintain ac-
tivated clotting time (ACT) values of 180–200 s.12 In costs, such as patient time or production losses, were
included. Cost and charges before angioplasty andthe control group, heparin was discontinued once at
least 1 h before manual compression. actual expense for PVS itself were excluded.
Analysis included comparison between groups ofDemographic data gathered included relevant ex-
clusion criteria, in addition to patient’s age, gender, time to haemostasis (minutes from sheath removal to
haemostasis), time to ambulation (hours from angio-and presence of diabetes or hypertension. Procedural
use of aspirin, ticlopidine, and other anticoagulant plasty to ambulation), length of hospitalisation (days
from angioplasty to discharge), pain perception (as-agents was recorded. ACT was measured immediately
before sheath removal in all patients. Assessment of sessed by VAS), hospital cost; and the incidence of
major groin complications (requiring surgical repairefficacy was defined as the time to haemostasis, the
time to ambulation, and the time to discharge. The and/or transfusion).
The Wilcoxon rank-sum test was used for alltime to haemostasis was defined as the elapsed time
Fig. 1. An overview of Prostar PlusÔ. After removing the sheath in femoral artery, Prostar PlusÔ is introduced along with the guidewire.
The guidewire comes from the tip of the Prostar PlusÔ and exits from the guidewire port as shown in the schema.
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Table 2. Comparisons of primary results.
PVS Group Control Group p Value
(n=30) (n=30)
BA (%) 13 (43) 18 (63) NS
Stent (%) 16 (53) 11 (36) NS
Rotablator (%) 1 (3) 1 (3) NS
Heparin dose (unit) 7900–6850 6000–7720 NS
ACT (s) 288–49 151–27 p<0.001
Time to haemostasis (min) 10–3 27–9 p<0.001
Time to ambulation (h) 2.2–0.9 11–1.4 p<0.001
Time to discharge (day) 2.2–0.4 3.1–0.7 p<0.001
Major complications
Surgical repair 0 0 NS
Transfusion 0 0 NS
Minor complications
Oozing 2 (6) 1 (3) NSFig. 2. Schematic drawing showing how the Prostar PlusÔ works.
Infection 1 (3) 0 NSBriefly, two pairs of needles with sutures come from the needle
AV fistula 0 0 NSport and penetrate arterial wall, and exit through hub. After making
Pseudoaneurysm 0 0 NSa knot of suture, the knot is pushed towards the surface of arterial
Distal embolisation 0 0 NSwall using the knot pusher. Immediately after the device is removed,
Haematomathe suture is firmly tied and haemostasis is completed.
2–5 cm 3 (10) 5 (16) NS
>5 cm 1 (3) 5 (13) p<0.05
Table 1. Baseline characteristics of study group. Data are presented as mean value–s.d. or number (%) of patients.
PVS=percutaneous vascular surgical device; BA=balloon angio-PVS Group Control Group p Value plasty; ACT=activated clotting time; AV fistula=arteriovenous fis-(n=30) (n=30) tula.
Age (year) 63–10 61–12 NS
Male (%) 27 (90) 25 (83) NS
In one patient, who was the second case in thisPrevious MI (%) 19 (63) 14 (46) NS
Re-PTCA (%) 18 (60) 15 (50) NS study, PVS deployment was unsuccessful; the success
Hypertension (%) 16 (53) 18 (60) NS rate for PVS deployment was therefore 96.6% (29 of
Diabetes (%) 13 (43) 12 (40) NS
30). Table 2 shows the primary results. PVS shortenedSmoking (%) 21 (70) 25 (83) NS
18 (60) 19 (63) NSHypercholesterolaemia (%) the time to haemostasis by as long as approximately
BMI (%) 23.7–3.0 23.9–2.7 NS 20 min. Patients in the PVS group were able to am-
PT (%) 95–3 94–4 NS
bulate 2.2 s.d. 0.9 h after sheath removal, 8 h earlierPTT (s) 30.8–4.1 30.0–3.8 NS
Platelet count ·103/ ml 24.4–8.6 27.1–5.8 NS than patients in the control group. Similar results were
found in the time to discharge.
Data are presented as mean value–s.d. or number (%) of patients.
There were no major groin complications (surgicalPVS=percutaneous vascular surgical device; BMI=body mass
index; MI=myocardial infarction; PTCA=percutaneous trans- repair or transfusion) in either group. One patient in
luminal coronary angioplasty; PT=prothrombin time; PTT=partial the PVS group had an infection at the access site,
thromboplastin time.
which was well treated with antibiotics. Oozing of
blood was found in two patients of the PVS group, andcomparisons of time and for VAS-derived variables.
in one patient of the control group. Large haematomasFisher’s exact test was used for analysis of major
([5 cm) developed more frequently in the controlcomplications.
group than in the PVS group (p<0.05).Categorical variables are expressed as frequencies
Table 3 shows the influence of interventional pro-and percentages, whereas continuous variables are
cedures, stent, and balloon angioplasty (BA). Re-presented as mean and standard deviation (s.d.). Dif-
gardless of procedures, PVS shortened the time toferences were considered significant at p<0.05.
haemostasis and the time to ambulation significantly,
even under strong anticoagulation, compared with
control manual compression. However, PVS was foundResults
to have significantly beneficial effect on the time to
discharge and hospital cost in only the stent group,A total of 60 patients were enrolled in this study. Thirty
patients were randomised to the manual compression but not in the BA group.
Hospital cost was to be estimated approximatelycontrol group, and the remaining 30 patients to the
PVS group. The baseline characteristics of both groups $300 less in the PVS group than in the control group
($1301–248 vs. 1613–460, p<0.05). Especially in stentare summarised in Table 1, showing that there were
no significant differences in characteristics. cases, PVS saved approximately $400 of the hospital
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Table 3. Influence of interventional procedure.
Stent BA
PVS Control p Value PVS Control p Value
(n=16) (n=11) (n=13) (n=18)
ACT (s) 316–42 168–14 p<0.001 243–34 158–35 p<0.001
Time to haemostasis (min) 10–2 29–10 p<0.001 10–5 23–3 p<0.001
Time to ambulation (h) 2.8–2.2 12.0–1.0 p<0.001 2.0–1.1 10.2–0.9 p<0.001
Time to discharge (day) 2.3–0.5 3.3–0.4 p<0.001 2.1–0.9 2.5–0.8 NS
Hospital cost ($) 1308–325 1750–427 p<0.01 1298–435 1549–420 NS
Data are presented as mean value–s.d. BA=balloon angioplasty; PVS=percutaneous vascular surgical device; ACT=activated clotting
time.
patients (24 out of 30) preferred PVS as a haemostasis
procedure if a repeat intervention was needed. In
particular, patients who had previously undergone
angioplasty with manual compression, 94.4% of the
patients (17 out of 18) preferred PVS for a subsequent
coronary intervention.
Discussion
We found that the Prostar PlusÔ shortened the time
Fig. 3. Serial changes in the discomfort level assessed by using two, to haemostasis and patient immobility, and decreased
ten-point standard visual analogue scales. Patient discomfort was local vascular complications, such as haematoma de-
rated on a 0-to-10 scale, in which rate 0 is “no pain” and rate 10 is
velopment. These results were obtained despite ag-“maximal degree of pain” the patient has experienced, respectively.
Closed circles indicate the control group, and open circles indicate gressive anticoagulation with a prolonged ACT over
the percutaneous vascular surgical device (PVS) group, respectively. 250 s (Tables 2 and 3). In contrast to the PVS, con-
The data show mean–s.d. (* p<0.01 vs. control).
ventional manual compression required ap-
proximately 20 min more for haemostasis, and 8 hcost compared with the control group (Table 3). How-
ever, because the actual expense for PVS is $350 in more for ambulation, even with a moderate increase
in ACT of>150 s. Moreover, as shown in Fig. 3, earlierour institute, these cost-saving benefits were cancelled.
Figure 3 shows serial changes in the discomfort level mobility by Prostar PlusÔ significantly increased
patient comfort, assessed by VAS. This may contributeassessed by VAS between the two patient groups. In
the control group, patient discomfort increased time- to patient preference of this PVS for haemostasis (Table
4). All patients, except one who had previously under-dependently until ambulation. However, PVS sig-
nificantly ameliorated patient discomfort in this bed- gone angioplasty with manual compression, expressed
a preference for PVS for a subsequent coronary inter-rest period (during dressing, after dressing, and before
ambulation). Before discharge, we asked all patients vention.
We had expected that the earlier mobility of patientsin the PVS group about their preference as to a hae-
mostasis procedure. As shown in Table 4, 80.0% of the using PVS would permit earlier discharge times,
Table 4. Patients survey (questionnaire).
PVS group (n=30) p Value
First PTCA Re-PTCA
(n=12) (n=18)
Preference of haemostasis procedure if a repeat
intervention is needed
Yes 7 (58.3) 17 (94.4) p<0.01
No 1 (8.3) 0 (0) NS
Unknown 4 (33.3) 1 (5.5) NS
Data are presented as number (%) of patients. PVS=percutaneous vascular surgical device;
PTCA=percutaneous transluminal coronary angioplasty.
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